Bionexus Gene Lab Corp (BGLC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 1,975 | 2,382 | 2,273 | 2,554 | 2,567 |
| Cost of Goods | 1,686 | 2,017 | 2,007 | 2,199 | 2,227 |
| Gross Profit | 289 | 365 | 267 | 354 | 340 |
| Operating Expenses | 715 | 461 | 15 | 3,082 | 839 |
| Operating Income | 259 | -79 | 258 | -2,529 | -272 |
| Interest Expense | 50 | 29 | 0 | 0 | 0 |
| Other Income | 45 | 24 | -4 | -4 | -3 |
| Pre-tax Income | 255 | -84 | 254 | -2,533 | -275 |
| Income Tax | 56 | 20 | -55 | 76 | -16 |
| Net Income Continuous | 199 | -104 | 309 | -2,609 | -259 |
| Net Income | $199 | $-104 | $309 | $-2,609 | $-259 |
| EPS Basic Total Ops | 0.11 | -0.01 | 1.88 | -1.57 | -0.41 |
| EPS Basic Continuous Ops | 0.11 | -0.01 | 1.62 | -1.56 | -0.18 |
| EPS Diluted Total Ops | 0.11 | -0.01 | 1.88 | -1.57 | -0.41 |
| EPS Diluted Continuous Ops | 0.11 | -0.01 | 1.62 | -1.56 | -0.18 |
| EPS Diluted Before Non-Recurring Items | 0.10 | -0.20 | N/A | N/A | N/A |
| EBITDA(a) | $340 | $-21 | $287 | $-2,499 | $-248 |